How induced pluripotent stem cells are redefining personalized medicine

Gene

Volumn 520, Issue 1, 2013, Pages 1-6

  Ferreira, Leonardo M R ^a   Mostajo Radji, Mohammed A ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Disease modeling; Regenerative medicine; Reprogramming; Stem cells

Indexed keywords

CYTOLOGY; DNA SEQUENCE; DNA STRAND; GENE TARGETING; GENETIC VARIABILITY; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNOGENICITY; NEURAL STEM CELL; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW;

ANIMALS; GENETIC DISEASES, INBORN; HUMANS; INDIVIDUALIZED MEDICINE; INDUCED PLURIPOTENT STEM CELLS; NUCLEAR REPROGRAMMING;

IPS;

EID: 84875806444     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.02.037     Document Type: Review

References (110)

1. Ahfeldt T., et al. Programming human pluripotent stem cells into white and brown adipocytes. Nat. Cell Biol. 2012, 14:209-219.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
3. An M.C., et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012, 11:253-263.
4. Anokye-Danso F., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8:376-388.
5. Apostolou E., Hochedlinger K. Stem cells: iPS cells under attack. Nature 2011, 474:165-166.
6. Berninger B. Making neurons from mature glia: a far-fetched dream?. Neuropharmacology 2010, 58:894-902.
7. Berninger B., et al. Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. J. Neurosci. 2007, 27:8654-8664.
8. Bock C., et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011, 144:439-452.
9. Bongso A., Fong C.Y., Ng S.C., Ratnam S. Isolation and culture of inner cell mass cells from human blastocysts. Hum. Reprod. 1994, 9:2110-2117.
10. Bonizzi G., Cicalese A., Insinga A., Pelicci P.G. The emerging role of p53 in stem cells. Trends Mol. Med. 2012, 18:6-12.
11. Buganim Y., et al. Direct reprogramming of fibroblasts into embryonic Sertoli-like cells by defined factors. Cell Stem Cell 2012, 11:373-386.
12. Caiazzo M., et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011, 476:224-227.
13. Campbell K.H., McWhir J., Ritchie W.A., Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996, 380:64-66.
14. Chen J., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
15. Chen J., et al. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat. Genet. 2012, 45(1):34-43.
16. Cherry A.B., Daley G.Q. Reprogramming cellular identity for regenerative medicine. Cell 2012, 148:1110-1122.
17. Chin M.H., et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009, 5:111-123.
18. Choi J., Costa M.L., Mermelstein C.S., Chagas C., Holtzer S., Holtzer H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7988-7992.
19. Cohen D.E., Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nat. Rev. Genet. 2011, 12:243-252.
20. Cowan C.A., Atienza J., Melton D.A., Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005, 309:1369-1373.
21. Davis R.L., Weintraub H., Lassar A.B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987, 51:987-1000.
22. De Carvalho D.D., You J.S., Jones P.A. DNA methylation and cellular reprogramming. Trends Cell Biol. 2010, 20:609-617.
23. Devine M.J., et al. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat. Commun. 2011, 2:440.
24. Ding, Q., Lee, Y.K., Schaefer, E.A.K., Peters, D.T., A., V., Kim, K., Kuperwasser, N., Motola, D.L., Meissner, T.B., Hendriks, W.T., Trevisan, M., Gupta, R.M., Moisan, A., Banks, E., Friesen, M., Schinzel, R.T., Xia, F., Tang, A., Xia, Y., Figueroa, E., Wann, A., Ahfeldt, T., Daheron, L., Zhang, F., Rubin, L.L., Peng, L.F., Chung, R.T., Musunuru, K., Cowan, C.A., in press. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12(2), 238-251.
25. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
26. Easley C.A.T., et al. Direct differentiation of human pluripotent stem cells into haploid spermatogenic cells. Cell Rep. 2012, 2:440-446.
27. Efe J.A., et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat. Cell Biol. 2011, 13:215-222.
28. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292:154-156.
29. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
30. Ferreira L.M. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol. 2010, 89:372-380.
31. Ferreira L.M., Floriddia E.M., Quadrato G., Di Giovanni S. Neural regeneration: lessons from regenerating and non-regenerating systems. Mol. Neurobiol. 2012, 46:227-241.
32. Ferreira L.M., Hebrant A., Dumont J.E. Metabolic reprogramming of the tumor. Oncogene 2012, 31:3999-4011.
33. Fong C.T., Brodeur G.M. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet. Cytogenet. 1987, 28:55-76.
34. Gordan J.D., Thompson C.B., Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113.
35. Guenther M.G., et al. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 2010, 7:249-257.
36. Gurdon J.B. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J. Embryol. Exp. Morphol. 1962, 10:622-640.
37. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
38. Hanna J., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
39. Hanna J.H., Saha K., Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010, 143:508-525.
40. Hayashi K., Ohta H., Kurimoto K., Aramaki S., Saitou M. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell 2011, 146:519-532.
41. Hayashi K., Ogushi S., Kurimoto K., Shimamoto S., Ohta H., Saitou M. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. Science 2012, 338:971-975.
42. Heins N., et al. Glial cells generate neurons: the role of the transcription factor Pax6. Nat. Neurosci. 2002, 5:308-315.
43. Hockemeyer D., et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 2009, 27:851-857.
44. Israel M.A., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
45. Karumbayaram S., et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 2009, 27:806-811.
46. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
47. Kawamura T., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
48. Kim J., et al. Reprogramming of postnatal neurons into induced pluripotent stem cells by defined factors. Stem Cells 2011, 29:992-1000.
49. Lapidot T., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
50. Li X., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
51. Li H., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
52. Li H., et al. p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell 2012, 11:845-852.
53. Li L.B., Chang K.H., Wang P.R., Hirata R.K., Papayannopoulou T., Russell D.W. Trisomy correction in down syndrome induced pluripotent stem cells. Cell Stem Cell 2012, 11:615-619.
54. Lumelsky N., Blondel O., Laeng P., Velasco I., Ravin R., McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 2001, 292:1389-1394.
55. Mani S.A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
56. Mardis E.R. A decade's perspective on DNA sequencing technology. Nature 2011, 470:198-203.
57. Marion R.M., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
58. Markoulaki S., et al. Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat. Biotechnol. 2009, 27:169-171.
59. Marqués-Torrejón, M.A., Porlan, E., Banito, A., Gómez-Ibarlucea, E., Lopez-Contreras, A.J., Fernández-Capetillo, O., Vidal, A.R., Gil, J., Torres, J., Farinas, I., in press. Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression. Cell Stem Cell 12(1), 88-100.
60. Masip M., Veiga A., Izpisua Belmonte J.C., Simon C. Reprogramming with defined factors: from induced pluripotency to induced transdifferentiation. Mol. Hum. Reprod. 2010, 16:856-868.
61. Mikkelsen T.S., et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008, 454:49-55.
62. Miles G.B., Yohn D.C., Wichterle H., Jessell T.M., Rafuse V.F., Brownstone R.M. Functional properties of motoneurons derived from mouse embryonic stem cells. J. Neurosci. 2004, 24:7848-7858.
63. Mummery C. Induced pluripotent stem cells - a cautionary note. N. Engl. J. Med. 2011, 364:2160-2162.
64. Musunuru K., et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010, 466:714-719.
65. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
66. Park I.H., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
67. Pearl J.I., Kean L.S., Davis M.M., Wu J.C. Pluripotent stem cells: immune to the immune system?. Sci. Transl. Med. 2012, 4:164ps25.
68. Polo J.M., et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 2010, 28:848-855.
69. Pralong D., Trounson A.O., Verma P.J. Cell fusion for reprogramming pluripotency: toward elimination of the pluripotent genome. Stem Cell Rev. 2006, 2:331-340.
70. Qian L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598.
71. Rama P., Matuska S., Paganoni G., Spinelli A., De Luca M., Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. N. Engl. J. Med. 2010, 363:147-155.
72. Ramalho-Santos J. Human procreation in unchartered territory: new twists in ethical discussions. Hum. Reprod. 2011, 26:1284-1287.
73. Ring K.L., et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012, 11:100-109.
74. Romli F., Alitheen N.B., Hamid M., Ismail R., Rahman N.M. Current techniques in reprogramming cell potency. J. Cell. Biochem. 2012.
75. Rouaux C., Arlotta P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. Nat. Cell Biol. 2013, 15:214-221.
76. Sanjana N.E., Cong L., Zhou Y., Cunniff M.M., Feng G., Zhang F. A transcription activator-like effector toolbox for genome engineering. Nat. Protoc. 2012, 7:171-192.
77. Schepers A.G., et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
78. Schinzel R.T., et al. Efficient culturing and genetic manipulation of human pluripotent stem cells. PLoS One 2011, 6:e27495.
79. Selvaraj V., Plane J.M., Williams A.J., Deng W. Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies. Trends Biotechnol. 2010, 28:214-223.
80. Sheldon S., Poulton K. HLA typing and its influence on organ transplantation. Methods Mol. Biol. 2006, 333:157-174.
81. Silva J., Chambers I., Pollard S., Smith A. Nanog promotes transfer of pluripotency after cell fusion. Nature 2006, 441:997-1001.
82. Sneddon J.B., Borowiak M., Melton D.A. Self-renewal of embryonic-stem-cell-derived progenitors by organ-matched mesenchyme. Nature 2012, 491:765-768.
83. Son E.Y., et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 2011, 9:205-218.
84. Song K., et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485:599-604.
85. Stadtfeld M., Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev. 2010, 24:2239-2263.
86. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
87. Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., el-Houseini M.E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994, 9:3389-3396.
88. Strominger J.L. Human histocompatibility proteins. Immunol. Rev. 2002, 185:69-77.
89. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
90. Takahashi K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
91. Takazawa T., Croft G.F., Amoroso M.W., Studer L., Wichterle H., Macdermott A.B. Maturation of spinal motor neurons derived from human embryonic stem cells. PLoS One 2012, 7:e40154.
92. Taylor S.M., Jones P.A. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979, 17:771-779.
93. Taylor C.J., Peacock S., Chaudhry A.N., Bradley J.A., Bolton E.M. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 2012, 11:147-152.
94. Tennant D.A., Durán R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10:267-277.
95. Thomson J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
96. Tubiana M., Koscielny S. On clonogenic tumour cells and metastasis-forming cells. Nat. Rev. Cancer 2008, 8:990.
97. Urnov F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11:636-646.
98. Wang T., et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell 2011, 9:575-587.
99. Warren L., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
100. Wernig M., et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat. Biotechnol. 2008, 26:916-924.
101. Winston R. The promise of cloning for human medicine. BMJ 1997, 314:913-914.
102. Xie H., Ye M., Feng R., Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004, 117:663-676.
103. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 2012, 10:678-684.
104. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
105. Yu J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
106. Yu J., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
107. Zhang D., et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 2009, 19:429-438.
108. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
109. Zhou Q., Brown J., Kanarek A., Rajagopal J., Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008, 455:627-632.
110. Zhou H., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384.